Breast Cancer Research and Treatment

, Volume 123, Issue 2, pp 563–567 | Cite as

TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects

  • Li-Xin Qiu
  • Lei Yao
  • Chen Mao
  • Bo Chen
  • Ping Zhan
  • Kai Xue
  • Jian Zhang
  • Hui Yuan
  • Xi-Chun Hu


Published data on the association between TGFB1 L10P polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between them. A total of 30 studies including 20,401 cases and 27,416 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with TGFB1 10P allele when all studies were pooled into the meta-analysis (LP vs. LL: OR = 1.046, 95% CI = 1.003–1.090; dominant model: OR = 1.052, 95% CI = 1.012–1.095). In the subgroup analysis by ethnicity, statistically significantly elevated risk was found in Caucasians (dominant model: OR = 1.045, 95% CI = 1.001–1.091). When stratified by study design, statistically significantly elevated risk was found based on population-based studies (dominant model: OR = 1.076, 95% CI = 1.019–1.136). In conclusion, this meta-analysis suggests that the TGFB1 10P allele may be a low-penetrant risk factor for developing breast cancer. However, large sample and representative population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding.


TGFB1 Polymorphism Breast cancer Susceptibility Meta-analysis 


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  2. 2.
    Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85CrossRefPubMedGoogle Scholar
  3. 3.
    Fujii D, Brissenden JE, Derynck R, Francke U (1986) Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet 12:281–288CrossRefPubMedGoogle Scholar
  4. 4.
    Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8:93–97CrossRefPubMedGoogle Scholar
  5. 5.
    Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y (2000) Association of a T29/C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101:2783–2787PubMedGoogle Scholar
  6. 6.
    Ziv E, Cauley J, Morin PA, Saiz R, Browner WS (2001) Association between the T29 → C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: the study of osteoporotic fractures. Jama 285:2859–2863CrossRefPubMedGoogle Scholar
  7. 7.
    Dunning AM, Ellis PD, McBride S (2003) A transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63:2610–2615PubMedGoogle Scholar
  8. 8.
    Hishida A, Iwata H, Hamajima N (2003) Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer 10:63–69CrossRefPubMedGoogle Scholar
  9. 9.
    Krippl P, Langsenlehner U, Renner W (2003) The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett 201:181–184CrossRefPubMedGoogle Scholar
  10. 10.
    Jin Q, Hemminki K, Grzybowska E (2004) Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer 112:94–99CrossRefPubMedGoogle Scholar
  11. 11.
    Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE (2004) T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 13:412–415PubMedGoogle Scholar
  12. 12.
    Saha A, Gupta V, Bairwa NK, Malhotra D, Bamezai R (2004) Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5′-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet 31:37–42CrossRefPubMedGoogle Scholar
  13. 13.
    Kaklamani VG, Baddi L, Liu J (2005) Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res 65:3454–3461PubMedGoogle Scholar
  14. 14.
    Lee KM, Park SK, Hamajima N (2005) Genetic polymorphisms of TGF-beta1 and TNF-beta and breast cancer risk. Breast Cancer Res Treat 90:149–155CrossRefPubMedGoogle Scholar
  15. 15.
    Shin A, Shu XO, Cai Q, Gao YT, Zheng W (2005) Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev 14:1567–1570CrossRefPubMedGoogle Scholar
  16. 16.
    Feigelson HS, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE (2006) Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 15:1236–1237CrossRefPubMedGoogle Scholar
  17. 17.
    Scola L, Vaglica M, Crivello A (2006) Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 1089:104–109CrossRefPubMedGoogle Scholar
  18. 18.
    Cox DG, Penney K, Guo Q (2007) TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses’ Health Study. BMC Cancer 7:175–181CrossRefPubMedGoogle Scholar
  19. 19.
    Cox A, Dunning AM, Garcia-Closas M (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352–358CrossRefPubMedGoogle Scholar
  20. 20.
    Rajkumar T (2008) TGFb1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFb1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112:81–87CrossRefPubMedGoogle Scholar
  21. 21.
    Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129CrossRefGoogle Scholar
  22. 22.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  23. 23.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  24. 24.
    Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17Google Scholar
  25. 25.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  26. 26.
    Taylor SJ, Tweedie RI (1998) Practical estimates of the effect of publication bias in meta- analysis. Australas Epidemiol 5:14–17Google Scholar
  27. 27.
    Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6:506–520CrossRefPubMedGoogle Scholar
  28. 28.
    Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117–129CrossRefPubMedGoogle Scholar
  29. 29.
    Hirschhorn JN, Lohmueller K, Byrne E (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61CrossRefPubMedGoogle Scholar
  30. 30.
    Wacholder S, Chanock S, Garcia-Closas M (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434–442CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Li-Xin Qiu
    • 1
    • 2
  • Lei Yao
    • 3
  • Chen Mao
    • 4
  • Bo Chen
    • 5
  • Ping Zhan
    • 6
  • Kai Xue
    • 1
    • 2
  • Jian Zhang
    • 1
    • 2
  • Hui Yuan
    • 7
  • Xi-Chun Hu
    • 1
    • 2
  1. 1.Department of Medical Oncology, Cancer HospitalFudan UniversityShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life SciencesFudan UniversityShanghaiChina
  4. 4.Department of Epidemiology, School of Public Health and Tropical MedicineSouthern Medical UniversityGuangzhouChina
  5. 5.Department of Geriatrics, First Affiliated HospitalNanjing Medical UniversityNanjingChina
  6. 6.Department of Respiratory MedicineNanjing Chest HospitalNanjingChina
  7. 7.Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical UniversityHefeiChina

Personalised recommendations